Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Intellectual Property Watch

Intellectual Property Law

: Intellectual Property Watch

Too Pricy For A Patent? Glivec Rejected

By Intellectual Property Watch

Novartis?s patent application for Glivec, a blood cancer drug, was recently ruled not patentable by the Intellectual Property Appellate Board of India (IPAB) for failing to meet the requirements under section 3(d) of the Indian Patent Act, which states that a pharmaceutical derivative must demonstrate enhanced ?efficacy? over the prior known molecule, according to Indian [...]

Full post as published by Intellectual Property Watch on July 09, 2009 (boomark / email).